Welcome to MS Australia
As widely reported in the media, the Prime Minister, the Hon Scott Morrison MP, today announced approval for the listing of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS) from 1 January 2019.
Previously, MAVENCLAD® was registered for use in Australia by the Therapeutic Goods Administration (TGA), for the treatment of patients with RRMS, to reduce inflammation in the nervous...
There are currently no Upcoming Events. Please check again soon!